Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Hematologist who treat patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Articles with lock require a subscription to GLG News | Request a free trial
November 10, 2008
Rainfall unlikely to be direct culprit to the Autism Pandemic
Analysis of: Autism linked with rainfall in study | www.boston.com
Author: GLG Expert Contributor
A recent study infers taht periods of increased rainfall could be linked to increase in number of children dioagnosed with autism. The causla l;ink of rainfall is unlikely, but most probably reflects other factors like children staying more indoors and thus watch more TV, get less sun exposure and...
November 10, 2008
Avastin for GBM: modest efficacy and soon to be approval
Analysis of: Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer | www.gene.com
Author: GLG Expert Contributor
Genetech's Avastin have shown modest increase in progresion free survival and overall survival in patients with gliobalstoma multiforme, the most common and most agressive malignant brain tumor With such data, Avastin is expected to join Temodar as chemotherapy agent approved for this tumor with...
November 10, 2008
Is Pharma's Head in the Sand??
Analysis of: Pharma need not worry too much about President Obama | www.pharmatimes.com
Author: GLG Expert Contributor
The implication is that our new chief executive has "bigger fish to fry" than attaching drug costs??
November 6, 2008
GSK to cut sales force , but......
Analysis of: Glaxo Plans 12% Reduction in Its U.S. Drug Sales Force | online.wsj.com
Author: GLG Expert Contributor
"As part of the restructuring, the company plans to group its sales staff around specific treatment areas" including oncology, probably
November 6, 2008
Avastin in Glioblastomas: I believe approval will be....
Analysis of: Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer | www.gene.com
Author: GLG Expert Contributor
Genetech is seeking FDA approval for use in the most malignant of brain tumors, Glioblastomas.
November 3, 2008
Apidra for Diabetes: No much innovation but will get some use
Analysis of: FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes | www.pipelinereview.com
Author: GLG Expert Contributor
Sanofi's rapid acting insulin formulation got FDA approval for use in children 4 years and older with Type I insulin dependent diabetes. The drug has rapid action so it may replace lispro and older short acting  insulin preparations, if the price tag is not prohibitive.
Donald FlemingOctober 28, 2008
The TKI's are building on their success
Analysis of: Phase II Trial of Sorafenib in Advanced Thyroid Cancer | jco.ascopubs.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
TKI's have been establihed in a small number of refractory solid cancers With slow migration to other venues, we are seeing new applications
Donald FlemingOctober 28, 2008
Vaccine for prostate cancer fails
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Recent Cell Genesys vaccine trial for prostate cancer fails The trial not only shows lack of efficacy, but possible harm from the vaccine arm of the trial
October 27, 2008
Nexavar - Vitamin "N" for Solid Tumors???
Analysis of: Phase II Trial of Sorafenib in Advanced Thyroid Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
Two Phase II trials show meanigful prolonged pFS in patients with iodine-refractory thyroid cancer who are treated with Sorafenib ( bayer/Onyx) The benefit needs to be confirmed in larger trials and need also to establish a favorable safety profile. Studies are needed for combination with other targeted...
October 27, 2008
Immunotherapy for cancer, still have ways to go
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: GLG Expert Contributor
Genesys terminated its studies of its cancer Vaccine for patients with refractory prostate cancer.  Cancer vaccine therapy remains limted to modest advantages in minimal residual diseases and in limted cases of melanoma and NHL

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 Next11 to 20 of 758

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747